Observations on new variant detected in Africa (Omicron)
-Many countries have closed borders, but I haven't heard of any that are simultaneously sending 10M vaccine doses to Africa.
-Closing borders while R>1 locally is silly. Virus is likely already widespread at v low freq.
-w/ no data, it's a bit shocking to see reputable people promoting 1 doctor's anecdotal observations that Omicron causes mild illness. If claim was opposite the same (always optimistic) scientist would demand to see data & suggest we don't believe it w/out rigorous analyses.
-interesting to see strong knee jerk reactions from reputable scientists (i.e. calling Omicron a scariant that we shouldn't worry about), while others take sequence data & mapping to make initial assessment that is worrisome:
-lots of folks pre-judging studies underway of neutralizing antibodies as not very valuable, despite strong data linking neutralizing antibodies to efficacy of vaccines (doi.org/10.1038/s41591…; medrxiv.org/content/10.110…)
-Some countries requiring 1 PCR test (sometimes post-arrival!) as if this will somehow stop introductions. It might reduce it a bit, but 1 test will miss many introductions. Only full 10d+ quarantine plus tests on day 10 will block most importations. @bencowling88
Here's what we know so far:
-Rise in cases in S Africa following subsiding of Delta wave (
What we don't know:
-Transmissibility of Omicron relative to Delta & contributions of infectiousness & immune escape (anyone seen data supporting higher prob of reinfection? who.int/news/item/26-1…)
-Differences in severity of illness
Since we don't have hard data on 3 things we want to know about new variants: transmissibility, immune escape, disease severity. What should we do?
-local precautionary approach: try to prevent establishment which requires reducing R/transmission via vaccines, masks, distancing &
reduce importation. Since variant is likely already widespread blocking travel from a few countries is ineffective. Need widespread quarantine & testing.
-global precautionary approach: immediately deploy vaccines in hardest hit areas (Africa)
-medium term adaptation approach: develop vaccine booster specific to this variant; likely underway
-long term approach: deploy vaccines globally to reduce transmission & probability of future variants arising
Example of ineffective approach discussed above (ban travel, when variant is already clearly locally established & Rt>1):
How do we get broad immunity to SARS-CoV-2 that will protect against future variants?
2 studies (are there more?) suggest that vaccination followed by infection gives broader protection than infection followed by vaccination. @florian_krammer@profshanecrotty@GuptaR_lab
1st paper (medrxiv.org/content/10.110…) shows: if you get vaccinated w/ mRNA vaccine & have a breakthrough Delta infection your subsequent antibodies are almost equally reactive in neutralizing Delta, Beta, Alpha, WT.
2nd paper (science.org/doi/10.1126/sc…) shows if you get infected (probably w/ D614G) then vaccinated w/ mRNA vaccine, your immunity is strong vs D614G & Delta but less so vs the most immune evasive variant so far, Beta.
Should we all get a vaccine booster (3rd dose)?
New preprint w @billy_gardner_ , we examine impact of 3rd doses on key topic: transmission. medrxiv.org/content/10.110…
tl;dr 3rd dose could significantly reduce Rt & stop some surges, but doses should 1st go to unvaccinated if possible
Background
COVID-19 vaccines are fantastic. Better than we could have imagined. mRNA vaccines had efficacy of ~95% for symptomatic disease & even better for severe disease & death. But there's now strong evidence that protection against mild disease & infection is waning a bit.
Here's one study from the UK (there are many others) showing a reduction for Pfizer &Astrazeneca. doi.org/10.1101/2021.0…
What is driving current peaks in SARS-CoV-2 cases & what does this mean for the fall & winter?
Although a peak might seem to indicate that we're headed for fewer cases until a new variant arises, unfortunately that's not the case & a surge is both likely & avoidable.
A thread.
One possibility is in nice thread @trvrb suggesting US Delta surge is peaking now b/c 5% more of US pop infected, driving Rt down to 1 (which occurs at peak).
Nice thread @EdMHill describing modeling from 1 of 3 teams on possible outcomes in UK that guided recent decision to postpone re-opening.
Big takeaways:
-I wish US gov had been open to scientific guidance in 2020
-Big uncertainty in behavior changes w/ re-opening
cont.
-Big uncertainty in relative transmissibility of delta (b.1.617.2) variant & vaccine effectiveness for transmission (not symptomatic disease). PHE-UK has provided fantastic real-time analyses of available data, but some critical data, that could be collected, are missing.
-Importance of limited vaccine supply. US can't seem to give away vaccine even with beer, lotteries & more. In UK (& most, but not all, of world) every dose is precious & in-demand.
Why hasn't B.1.1.7 fully displaced other variants in US? What other variants are persisting/growing?
Thread
B.1.1.7 has risen to relatively high frequencies in many states, but hasn't exceeded 90% in any of them & may be falling in several.
Data here from @my_helix
GISAID sequences via fantastic outbreak.info for US as a whole suggest B.1.1.7 now stable @70%, P.1 is growing, B.1.526 frequencies are stable. But variable sequencing means finer resolution is better for understanding frequency dynamics, spatial variability & nuance.
Statewide scale is still too large but better than whole US.
Here's FL. Similar pattern as whole US - P.1 growing & B.1.526 stable, leading to slight recent decrease in B.1.1.7
Yesterday I posted the tweet below as a joke.
Today I found so much bullshit (@callin_bull) it blows my mind.
Exhibit 1: The press release itself: investors.modernatx.com/news-releases/…
Yup, they claim 0 vs 4 cases = 100% efficacy.
Exhibit 2: NBC, USA today both parrot 100% efficacy claim.
Exhibit 3: Moderna CEO claims vaccine prevents infection (see quote). Note: there was no data presented from study on efficacy against infection (despite that being #1 reason to vaccinate kids). Only symptomatic disease (4 cases total), antibody response, & side effects.
It's worth noting that efficacy wasn't a primary endpoint of this trial - translation: the study wasn't trying to measure efficacy so there's no need for Moderna CEO to spout bullshit. Where is NIH partner telling them to cut the BS?